Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer
June 01 2022 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its leadership team will participate in five
upcoming events being hosted by respected epilepsy-focused patient
advocacy groups.
"We are pleased to be included in these key
epilepsy conferences this summer. The opportunity to understand the
perspectives of the community, from patients and families, to
advocacy leaders and to healthcare providers, is invaluable as we
advance our promising pipeline," stated Dr. Randall Kaye,
Longboard’s Chief Medical Officer. "We also look forward to sharing
more information on our ongoing Phase 1b/2a PACIFIC Study in people
living with developmental and epileptic encephalopathies, and our
plans for the future development of LP352 for the potential
treatment of seizures associated with a broad range of rare and
refractory epilepsies."
As part of our continuing commitment to support
and partner with the epilepsy community, Longboard will sponsor and
participate actively in these upcoming meetings*:
- Epilepsy Foundation Pipeline Conference, June
5-6, 2022, in Santa Clara, CA + Hybrid (presenting)
- Lennox-Gastaut Syndrome Foundation®
(LGSF) 8th International
Family & Professional Conference, June 17-19, 2022, in
Grapevine, TX (presenting)
- Dravet Syndrome Foundation (DSF), in collaboration with
Cook Children’s Medical Center, 5th
Biennial Family & Professional Conference,
June 23-25, 2022, in Fort Worth, TX (presenting)
- World Tuberous Sclerosis Complex (TSC)
Conference, co-hosted by the TSC Alliance® and Tuberous
Sclerosis Complex International (TSCi), July 28-31, 2022, in
Dallas, TX
- FamilieSCN2A Foundation’s Summer Seminar, July
28-29, 2022, in Columbus, OH (participating on roundtable)
*Participation is limited to registered guests of the
conferences.
About LP352LP352 is an oral,
centrally acting, 5-HT2c superagonist in development for the
potential treatment of seizures associated with developmental and
epileptic encephalopathies (DEEs) such as Dravet syndrome,
Lennox-Gastaut syndrome (LGS), tuberous sclerosis complex (TSC),
CDKL5 deficiency disorder (CDD), and other epileptic disorders.
LP352 is designed to modulate GABA and, as a result, suppress the
central hyperexcitability that is characteristic of seizures. LP352
has demonstrated negligible observed impact on 5-HT2b and 5-HT2a
receptor subtypes in our preclinical studies to date. 5-HT2b and
5-HT2a receptor agonism have been associated with significant
adverse side effects. LP352 has novel chemistry and attributes. It
was designed to be more specific and selective for the 5-HT2c
receptor subtype, giving it the potential to reduce seizures in
patients with DEEs while overcoming the known or perceived safety
limitations of available drugs in the 5-HT2 class. LP352 is
currently being evaluated in a Phase 1b/2a trial, the PACIFIC
Study, in participants with DEEs.
About DEEsDEEs refer to a group
of severe heterogeneous epilepsies that are characterized by drug
resistant seizures and significant developmental delay.
Importantly, if seizure control can be improved,
developmental delay may slow. Most DEEs begin early in life, often
starting in infancy. Children can have frequent and severe seizures
which may be of multiple types. Epileptic spasms, tonic or atonic
seizures and myoclonic seizures, among other seizure types, can be
seen. In many cases, seizures are life long, although in some
instances they can abate with time with certain syndromes or
specific causes. Learn more.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2c (5-HT2c) receptor superagonist, with
negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “look forward”, “plans”, “potential”, “will” and “focused
on”. Forward-looking statements include statements about
Longboard’s participation in the upcoming conferences, the value to
Longboard of such participation, Longboard’s clinical and
preclinical programs, including enrollment, their potential,
availability of additional information, plans, indications,
efficacy and safety, ability to develop and deliver medicines, and
focus. For such statements, Longboard claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
the forward-looking statements include, but are not limited to, the
following: Risks related to Pfizer’s acquisition of Arena;
Longboard’s limited operating history, financial position and need
for additional capital; Longboard will need additional managerial
and financial resources to advance all of its programs, and you and
others may not agree with the manner Longboard allocates its
resources; risks related to the development and commercialization
of Longboard’s product candidates; Longboard’s product candidates
are in the early phase of a lengthy research and development
process, the timing, manner and outcome of research, development
and regulatory review is uncertain, and Longboard’s product
candidates may not advance in research or development or be
approved for marketing; enrolling participants in Longboard’s
ongoing and intended clinical trials is competitive and
challenging; the duration and severity of the coronavirus disease
(COVID-19) outbreak, including but not limited to the impact on
Longboard’s clinical trials and operations, the operations of
Longboard’s suppliers, partners, collaborators, and licensees, and
capital markets, which in each case remains uncertain; risks
related to unexpected or unfavorable new data; nonclinical and
clinical data is voluminous and detailed, and regulatory agencies
may interpret or weigh the importance of data differently and reach
different conclusions than Longboard or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
topline data may not accurately reflect the complete results of a
particular study or trial; risks related to relying on licenses or
collaborative arrangements; other risks related to Longboard’s
dependence on third parties; competition; product liability or
other litigation or disagreements with others; government and
third-party payor actions, including relating to reimbursement and
pricing; risks related to regulatory compliance; and risks relate
to Longboard’s and third parties’ intellectual property rights.
Additional factors that could cause actual results to differ
materially from those stated or implied by Longboard’s
forward-looking statements are disclosed in Longboard’s filings
with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024